Device type · DJG
Enzyme Immunoassay, Opiates
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
DJG
Clinical Toxicology
Device class
Class II
FDA decisions since 2015
57
510(k), De Novo and PMA
Adverse event reports
4
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Enzyme Immunoassay, Opiates
- Product code
- DJG
- Device class
- Class II
- Review panel
- Clinical Toxicology
- Regulation
- 21 CFR 862.3650
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for DJG
Latest FDA decisions
The 8 newest of 57 since 2015.
K252684 · Decided Jan 29, 2026 · 157 days after receipt
Device type: Enzyme Immunoassay, Opiates (DJG) · Laboratory Medicine & Pathology
K250741 · Decided Jan 23, 2026 · 318 days after receipt
Device type: Enzyme Immunoassay, Opiates (DJG) · Laboratory Medicine & Pathology
K253082 · Decided Jan 16, 2026 · 115 days after receipt
Device type: Enzyme Immunoassay, Opiates (DJG) · Laboratory Medicine & Pathology
54 more FDA decisions with a free account
Reports received
4
Received Nov 1, 2025 to Nov 19, 2026. Includes 1 of another or unstated type.
Malfunction reports
2
50% of reports
Injury reports
1
25% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 1 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 2 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 1 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 1 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 1 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 1 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
- Unk1
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- False Positive Result4
- Non Reproducible Results1
- Use of Device Problem1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions3
- Distress1
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Illegally MarketedOpen, Classified
Z-0733-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
- Drug Test Small (4 substances)Open, Classified
Z-0734-2026 · Started Nov 3, 2025 · Posted by FDA Dec 1, 2025
Reason given: Distribution without premarket approval/clearance.
Cause as FDA categorized it: No Marketing Application
Ortho-Clinical Diagnostics, Inc.
Z-2073-2025 · Started Jun 12, 2025 · Posted by FDA Jul 2, 2025
Reason given: Lots from Generation (GEN) 15 of VITROS Chemistry Products OP Reagent may generate lower than expected quality control (QC) results. If the customer is unable to get passing quality control results, then the customer would be unable to run the OP-LO protocol leading to a potential delay in patient results.
Cause as FDA categorized it: Under Investigation by firm
10 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.